Project Grant R21AI190454
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$457K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop new antimicrobial agents and combination therapies to combat the growing threat of Gram-negative bacterial pathogens, specifically carbapenem-resistant Acinetobacter baumannii (CRAB) and Klebsiella pneumoniae (CRKP). The $2,308,174 award, with a performance period from August 2024 to May 2029, will fund three...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research, will support research to identify synergistic dual-aminoglycoside combinations that are effective against multidrug-resistant (MDR) Gram-negative bacteria. The $475,036 award, with a period of performance from April 11, 2025 to March 31, 2027, will enable researchers at the University of Illinois to: 1) Identify dual-aminoglycoside...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Methodist Hospital Research Institute in the amount of $259,461 to investigate the mechanisms of resistance and clinical outcomes of non-carbapenemase producing carbapenem-resistant Klebsiella pneumoniae (NCP-KPN) infections. The research aims to characterize the genomic factors associated with discordant carbapenem susceptibility phenotypes in...
This Project Grant award of $392,634, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel nanoimmunotherapeutic approach to combat multidrug-resistant (MDR) bacterial infections. The project aims to design, fabricate, and optimize a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that can sensitize bacteria to host oxidant killing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $383,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Nebraska Medical Center (UNMC) to discover novel antimicrobial peptides that can effectively eliminate drug-resistant gram-negative bacteria. The project aims to elucidate the structure-activity relationship, toxicity, pharmacokinetics, and in vivo efficacy of a novel antimicrobial peptide called Verine...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), funds research focused on developing novel antibiotics to address the growing threat of multi-drug resistant bacterial pathogens. The $749,417 award to President and Fellows of Harvard College supports the synthesis and biological evaluation of new antibiotic compounds that target the lipoprotein transport...
This federal Project Grant award of $249,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to define the mechanisms by which macrophages (a type of immune cell) restrict the growth of the bacterium Klebsiella pneumoniae (KP) during bloodstream infections (bacteremia). The central hypothesis is that tissue-resident macrophages provide distinct environments that either restrict or...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $661,693 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Iowa. The 5-year grant, awarded on June 16, 2025, supports research to define the structure and function of a new family of enzymes involved in peptidoglycan crosslinking in the opportunistic pathogen Clostridioides difficile. The research aims to provide foundational knowledge that could advance the...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $569,210 Project Grant to the University of Colorado Boulder. The five-year grant, effective February 1, 2025, supports research to structurally and functionally characterize three proteins responsible for antimicrobial resistance, screen for probes to define inhibitory strategies, and develop a platform to quantitatively test the impact of target...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $395,496 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Regents of the University of California, San Francisco (UCSF) effective August 23, 2024. The funding will support a research project titled "Metagenomic Surveillance of Pathogen and Antimicrobial Resistance Gene Transmission in Hospitalized Neonates." The project aims to leverage metagenomic next-generation sequencing...